GlassScriptPhysician profile
Amado Rueda
NPI 1750317061
$10,406.50
in general payments reported to CMS, 2019-2025
32 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $1,145 · 2021: $1,432 · 2022: $1,195 · 2023: $1,549 · 2024: $1,731 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,046 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,046.22 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,036.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,479.76 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,000.45 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $909.73 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $785.50 | 2020-2025 | Linzess, Viberzi, Synthroid |
| Abbott Laboratories | $745.72 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $439.15 | 2022-2024 | |
| Pfizer INC. | $331.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $326.52 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $297.54 | 2019-2023 | |
| Amarin Pharma, INC. | $248.33 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.75 | 2020-2023 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $211.02 | 2019-2021 | |
| Mylan Specialty L.P. | $185.60 | 2020-2023 | Yupelri |
| Allergan, INC. | $160.60 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $142.28 | 2019-2024 | Shingrix, Arexvy |
| Ardelyx, INC. | $125.51 | 2024-2025 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $117.72 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $115.28 | 2021-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $94.99 | 2023 | |
| Exact Sciences Corporation | $82.22 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $68.80 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $54.72 | 2021 | |
| Cranial Technologies, INC | $48.88 | 2021-2025 | Doc Band |
| E.R. Squibb & Sons, L.L.C. | $39.79 | 2021-2023 | Eliquis |
| Horizon Therapeutics Plc | $30.04 | 2019-2020 | |
| Shield Therapeutics INC | $22.90 | 2022 | |
| Sanofi Pasteur INC. | $19.90 | 2019 | |
| Linus Health, INC. | $16.20 | 2023 | |
| Seqirus USA INC | $16.07 | 2024 | Flucelvax, Fluad |
| Arbor Pharmaceuticals, INC. | $12.18 | 2021 | |
| Phathom Pharmaceuticals, INC. | $8.52 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amado Rueda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.